[go: up one dir, main page]

WO2010015538A3 - Predictive marker for egfr inhibitor treatment - Google Patents

Predictive marker for egfr inhibitor treatment Download PDF

Info

Publication number
WO2010015538A3
WO2010015538A3 PCT/EP2009/059641 EP2009059641W WO2010015538A3 WO 2010015538 A3 WO2010015538 A3 WO 2010015538A3 EP 2009059641 W EP2009059641 W EP 2009059641W WO 2010015538 A3 WO2010015538 A3 WO 2010015538A3
Authority
WO
WIPO (PCT)
Prior art keywords
egfr inhibitor
inhibitor treatment
predictive marker
predictive
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/059641
Other languages
French (fr)
Other versions
WO2010015538A2 (en
Inventor
Paul Delmar
Jean-Pierre Delord
Philippe Rochaix
Fabienne Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of WO2010015538A2 publication Critical patent/WO2010015538A2/en
Publication of WO2010015538A3 publication Critical patent/WO2010015538A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides a biomarker that is predictive for the response to treatment with an EGFR inhibitor in cancer patients.
PCT/EP2009/059641 2008-08-05 2009-07-27 Predictive marker for egfr inhibitor treatment Ceased WO2010015538A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161804.3 2008-08-05
EP08161804 2008-08-05

Publications (2)

Publication Number Publication Date
WO2010015538A2 WO2010015538A2 (en) 2010-02-11
WO2010015538A3 true WO2010015538A3 (en) 2010-04-08

Family

ID=41365170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/059641 Ceased WO2010015538A2 (en) 2008-08-05 2009-07-27 Predictive marker for egfr inhibitor treatment

Country Status (1)

Country Link
WO (1) WO2010015538A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012240240A1 (en) * 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
AU2012240246A1 (en) * 2011-04-04 2013-05-09 Netherlands Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
BR112014012495A2 (en) * 2011-11-25 2017-06-06 Assist Publique - Hopitaux De Paris in vitro method, kit, egfr inhibitor and method of treating cancer affected patients
KR20160089488A (en) * 2013-11-26 2016-07-27 인테그라겐 A method for predicting responsiveness to a treatment with an egfr inhibitor
GB2534879A (en) * 2015-02-03 2016-08-10 Stratton Richard The identification of genomic markers in the first intron of the LEPREL 1 gene which predict resistance or susceptibilty to fibrotic disorders
KR101764970B1 (en) 2015-06-10 2017-08-04 아주대학교산학협력단 Biomarker composition for diagnosing cancer with mitochondrial dysfunction comprising NUPR1 and method for diagnosing cancer using the same marker

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111273A2 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004111273A2 (en) * 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BARBARA A FREDERICK: "Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non small cell lung carcinoma", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 6, no. 6, 1 January 2007 (2007-01-01), pages 1683 - 1691, XP007909848, ISSN: 1535-7163 *
KALISH L H ET AL: "Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, no. 22, 15 November 2004 (2004-11-15), pages 7764 - 7774, XP009123018, ISSN: 1078-0432 *
MARK AGULNIK ET AL: "Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrenor Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 25, no. 15, 1 June 2007 (2007-06-01), pages 2184 - 2191, XP007909847, ISSN: 0732-183X *
THOMAS FABIENNE ET AL: "Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 23, 1 December 2007 (2007-12-01), pages 7086 - 7092, XP009123003, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
WO2010015538A2 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
WO2010146059A3 (en) Biomarkers for igf-1r inhibitor therapy
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2010009337A3 (en) Signatures and pcdeterminants associated with prostate cancer and methods of use thereof
DK2115472T3 (en) CANCER biomarkers
TN2013000464A1 (en) Biomarkers for hedgehog inhibitor therapy
LT2313364T (en) METHODS FOR THE DETERMINATION OF SYMMETRIC DIMETHYLARGININ
EP2304680A4 (en) Assessing tumor response to therapy
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
GB0902654D0 (en) Covariance based face association
MX2010001571A (en) Predictive markers for egfr inhibitor treatment.
WO2009021681A3 (en) Egfr inhibitor treatment marker
PT2356252E (en) Method for the urinary detection of bladder cancer
MX2010001579A (en) Predictive marker for egfr inhibitor treatment.
BRPI0815545A2 (en) PREDICTIVE MARKERS FOR TREATMENT WITH EGFR INHIBITORS
WO2010022268A9 (en) Markers for assessing the susceptibility of cancer to igf-1r treatment
WO2009021683A3 (en) Predictive marker for egfr inhibitor treatment
MX2010001580A (en) Predictive marker for egfr inhibitor treatment.
MX2010001573A (en) Predictive marker for egfr inhibitor treatment.
WO2013017891A3 (en) Assay
WO2009021684A3 (en) Predictive marker for egfr inhibitor treatment
HK40104791A (en) Cancer biomarkers
MX2010001570A (en) Predictive marker for egfr inhibitor treatment.
MX2010001572A (en) Predictive marker for egfr inhibitor treamtent.
AU2008900560A0 (en) Prostate cancer biomarkers
HK1202589A1 (en) Biomarkers for iap inhibitor therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09781105

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09781105

Country of ref document: EP

Kind code of ref document: A2